On October 13, 2023, TANG KEVIN C (Trades, Portfolio), a renowned investment firm, made a significant move in the stock market by acquiring 4,024,486 shares in Rain Oncology Inc (NASDAQ:RAIN). This transaction marked a new holding for the firm, with the shares purchased at a price of $0.98 each. The acquisition had a substantial impact on the firm's portfolio, accounting for 99.98% of its total holdings. As a result, TANG KEVIN C (Trades, Portfolio) now holds an 11.06% stake in Rain Oncology Inc.
About TANG KEVIN C (Trades, Portfolio)
Based in San Diego, California, TANG KEVIN C (Trades, Portfolio) is a prominent investment firm known for its strategic market moves. The firm's investment philosophy is centered around identifying and investing in companies with strong growth potential. Prior to this transaction, the firm's top holding was in Heron Therapeutics Inc (NASDAQ:HRTX).
Overview of Rain Oncology Inc
Rain Oncology Inc, a US-based biotechnology company, is focused on developing therapies that target oncogenic drivers. The company's approach involves selecting patients based on their tumors' underlying genetics rather than histology. Rain Oncology Inc's market capitalization stands at $36.012 million. Despite the company's promising business model, its stock performance has been underwhelming, with a PE percentage of 0.00, indicating that the company is currently operating at a loss. The GF Value of the stock is also not available, making it difficult to evaluate its valuation.
Financial Health of Rain Oncology Inc
When assessing the financial health of Rain Oncology Inc, several factors come into play. The company's balance sheet rank is 8/10, indicating a relatively strong financial position. However, its profitability rank is low at 1/10, and its growth rank is 0/10, suggesting that the company has struggled with profitability and growth. The company's cash to debt ratio is 425.07, ranking 270th in the industry.
Performance of Rain Oncology Inc in the Biotechnology Industry
In the biotechnology industry, Rain Oncology Inc's performance has been less than stellar. The company's ROE and ROA stand at -90.39 and -76.20 respectively, ranking 1053rd and 1228th in the industry. The company's gross margin growth and operating margin growth are both at 0.00, indicating no growth in these areas. Over the past three years, the company's EBITDA growth and earning growth have been negative, at -39.40 and -38.40 respectively.